Dimerix Secures A$34 Million Non-Dilutive Funding Facility

• Dimerix secures A$34 million non-dilutive funding facility
• Facility provides financial flexibility for clinical milestones
• Initial draw-down of 50% expected in September 2026

Dimerix Limited, a clinical-stage biopharmaceutical company focused on kidney disease treatments, has secured a A$34 million non-dilutive funding facility with a syndicate of Australian and U.S. independent lenders. The facility provides Dimerix with financial flexibility to support its clinical development programs, including the Phase 3 trial of DMX-200 for FSGS and the Phase 2 trial of DMX-652 for Acute Kidney Injury. Dimerix has elected to initially draw down only 50% of the committed funds, which is considered sufficient to complete all currently planned activities. The facility also provides the option to secure up to A$50 million in total commitments on or before March 31, 2027, although Dimerix currently has no plans to access this additional funding.